RYBP predicts survival of patients with non-small cell lung cancer and regulates tumor cell growth and the response to chemotherapy

Voruganti, Sukesh; Xu, Fanghua; Qin, Jiang‐Jiang; Guo, Yan; Sarkar, Sushanta; Gao, Ming; Zheng, Zhi‐Jie; Wang, Ming Hai; Zhou, Jianwei; Qian, Biyun; Zhang, Ruiwen; Wang, Wei

doi:10.1016/j.canlet.2015.09.003

Cited by 26 publications

(30 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, a growing body of evidence has demonstrated aberrant expression, chromosomal translocation, or missense mutation of multiple PcG members in a variety of cancers, suggesting an implication of the PcG deregulation in the cancer development . For example, Ring1 and YY1 binding protein (RYBP), a new member of the PcG family, has been found downregulated in hepatocellular and non–small cell lung cancers and enforced RYBP expression suppressed proliferation, induced apoptosis, and increased chemosensitivity of these cancer cells . These findings indicated the tumor‐suppressive effect of RYBP on cancer progression.…”

Section: Introductionmentioning

confidence: 99%

Overexpression of RYBP inhibits proliferation, invasion, and chemoresistance to cisplatin in anaplastic thyroid cancer cells via the EGFR pathway

Tong

Tan

Zhang

et al. 2018

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Ring1 and YY1 binding protein (RYBP), a new member of the polycomb group protein family, has been reported to play an important role in various biological processes.Recently, more and more studies have demonstrated an implication of RYBP in cancer development. However, the specific role of RYBP in anaplastic thyroid cancer (ATC) remains unknown. In this study, we investigated for the first time the expression pattern and biological functions of RYBP in ATC. We showed that RYBP was lowly expressed in ATC tissues and cell lines. We also found that overexpression of RYBP inhibited ATC cell proliferation, invasion, and cisplatin resistance. Furthermore, we observed that upregulation of RYBP decreased the phosphorylation of EGFR and ERK1/2 in ATC cells. Taken together, our data indicated that RYBP might be considered as a promising therapeutic target for the treatment of ATC. K E Y W O R D S anaplastic thyroid cancer (ATC), chemoresistance, invasion, proliferation, Ring1 and YY1 binding protein (RYBP)

show abstract

Section: Introductionmentioning

confidence: 99%

Overexpression of RYBP inhibits proliferation, invasion, and chemoresistance to cisplatin in anaplastic thyroid cancer cells via the EGFR pathway

Tong

Tan

Zhang

et al. 2018

J Biochem & Molecular Tox

View full text Add to dashboard Cite

show abstract

“…In the in vivo studies, the tumor tissue samples were homogenized in NP-40 lysis buffer and the supernatants were collected. The proteins from cell and tissue lysates were quantified, and the protein samples were then subjected to Western blotting analysis for the expression levels of MDM2, p53, and p21 using the methods described previously [39, 40]. …”

Section: Methodsmentioning

confidence: 99%

“…Tumor and tissue sections with a thickness of 5 µm were deparaffinized in xylenes, rehydrated, and washed with PBS. For the immunohistochemistry studies [39, 40], the tumor slides were incubated with a biotinylated antihuman MDM2 antibody (diluted 1:50 in 5% BSA in PBS) for 1 h at room temperature. For TUNEL staining [39, 40], tissue sections were incubated with proteinase K (20 µg/mL in 10 mM Tris-HCl, pH 7.4) for 15 min at 37°C.…”

Section: Methodsmentioning

confidence: 99%

“…For the immunohistochemistry studies [39, 40], the tumor slides were incubated with a biotinylated antihuman MDM2 antibody (diluted 1:50 in 5% BSA in PBS) for 1 h at room temperature. For TUNEL staining [39, 40], tissue sections were incubated with proteinase K (20 µg/mL in 10 mM Tris-HCl, pH 7.4) for 15 min at 37°C. DNA breaks were then labeled with terminal deoxytransferase (TdT) in a humidified chamber at 37°C for 5 min, followed by incubation with 50 µL of biotinylated bromodeoxyuridine antibody at 37°C for 1 h, and washing with PBS.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis

Qin

Wang

Sarkar

et al. 2016

Journal of Controlled Release

Self Cite

View full text Add to dashboard Cite

We have recently discovered a specific Murine Double Minute 2 (MDM2) oncogene inhibitor, called SP141, which exerts potent anticancer activity in various breast cancer models. However, its low oral bioavailability is the major hurtle for moving this drug to clinical trial. The present study was designed to discover and validate a novel nano-oral delivery system for this promising anticancer agent. Herein, we report the preparation, characterization, and evaluation of the efficacy and safety of the SP141-loaded IgG Fc-conjugated maleimidyl-poly(ethylene glycol)-co-poly(ε-caprolactone) (Mal-PEG-PCL) nanoparticles (SP141FcNP) as an orally cancer therapeutic agent. Our results indicated that SP141FcNP showed a biphasic release pattern and increased transepithelial transport in vitro and in vivo with the involvement of FcRn-mediated transcytosis. SP141FcNP also exhibited increased intestinal epithelial permeability, cellular uptake, and oral bioavailability, with extended blood circulation time, increased tumor accumulation, enhanced MDM2 inhibition, and stronger responses in anti-tumor growth and metastasis effects in vitro and in vivo, without apparent host toxicity. Collectively, this newly developed nanoparticle oral delivery system provides a basis for evaluation of SP141 as a potential clinical candidate for cancer therapy.

show abstract

“…Deregulation of PcG proteins disrupts this balance and often contributes to cell transformation and neoplasticity [48,49]. As mentioned previously, RYBP is a multifaceted adaptor involved in both the PcG complex and apoptosis; indeed, several studies have demonstrated dysregulated expression of RYBP in various human tumour tissues, including prostate, lung, liver, breast and cervical cancers, as well as Hodgkin's lymphoma (HL), and glioblastoma multiforme [43,[50][51][52][53][54][55][56][57]. Here, we will discuss the function of RYBP in these different types of cancer.…”

Section: The Roles Of Rybp In the Cancermentioning

confidence: 99%

Multiple roles of Ring 1 and YY1 binding protein in physiology and disease

Zhan

Wang

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

IntroductionThe roles of RYBP in development The roles of RYBP in the regulation of gene expression through the PcG complex and binding with transcriptional factorsThe roles of RYBP in the apoptosis The roles of RYBP in the cancer Concluding remarks Conflict of interest AbstractRing 1 and YY1 binding protein (RYBP) was first identified in 1999, and its structure includes a conserved Npl4 Zinc finger motif at the N-terminus, a central region that is characteristically enriched with arginine and lysine residues and a C-terminal region enriched with serine and threonine amino acids. Over nearly 20 years, multiple studies have found that RYBP functions as an organ developmental adaptor. There is also evidence that RYBP regulates the expression of different genes involved in various aspects of biological processes, via a mechanism that is dependent on interactions with components of PcG complexes and/or through binding to different transcriptional factors. In addition, RYBP interacts directly or indirectly with apoptosis-associated proteins to mediate anti-apoptotic or pro-apoptotic activity in both the cytoplasm and nucleus of various cell types. Furthermore, RYBP has also been shown to act as tumour suppressor gene in different solid tumours, but as an oncogene in lymphoma and melanoma. In this review, we summarize our current understanding of the functions of this multifaceted RYBP in physiological and pathological conditions, including embryonic development, apoptosis and cancer, as well as its role as a component of polycomb repressive complex 1.

show abstract

RYBP predicts survival of patients with non-small cell lung cancer and regulates tumor cell growth and the response to chemotherapy

Cited by 26 publications

References 31 publications

Overexpression of RYBP inhibits proliferation, invasion, and chemoresistance to cisplatin in anaplastic thyroid cancer cells via the EGFR pathway

Overexpression of RYBP inhibits proliferation, invasion, and chemoresistance to cisplatin in anaplastic thyroid cancer cells via the EGFR pathway

Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis

Multiple roles of Ring 1 and YY1 binding protein in physiology and disease

Contact Info

Product

Resources

About